Skip to content

Type 1 diabetes — overview

TL;DR — Type 1 diabetes (T1D) is a chronic autoimmune disease in which T-cell-mediated destruction of pancreatic β cells produces lifelong dependence on exogenous insulin; it is now formally staged as a continuum that begins years before symptoms, with multiple islet autoantibodies defining presymptomatic stage 1 (Insel 2015, PMID 26404926). Roughly 8.4 million people lived with T1D worldwide in 2021 — most of them adults — with prevalence projected to reach 13.5–17.4 million by 2040 (Gregory 2022, PMID 36113507). Intensive glycemic control prevents complications (DCCT 1993, PMID 8366922), and automated insulin delivery has become the technology standard of care (Brown 2019, PMID 31618560; ADA 2026, PMID 41358889). The field's frontier has shifted from managing the disease to modifying it: teplizumab delays clinical onset by a median ~2 years in at-risk relatives (Herold 2019, PMID 31180194), and stem-cell-derived islets rendered 10 of 12 recipients insulin-independent at one year in an early trial (Reichman 2025, PMID 40544428). The biggest unknowns are whether disease modification can be extended into durable prevention, and how to close the enormous global gap in outcomes.

Definition and diagnostic anchors

  • T1D results from autoimmune β-cell destruction, marked by islet autoantibodies (against insulin, GAD65, IA-2, ZnT8) and near-total loss of endogenous insulin secretion; diagnosis and classification criteria are maintained in the ADA Standards of Care (ADA 2026, PMID 41358893).
  • Staging framework (2015) — the JDRF/Endocrine Society/ADA scientific statement defines Stage 1 (≥2 islet autoantibodies, normoglycemia, presymptomatic), Stage 2 (autoimmunity + dysglycemia, presymptomatic), and Stage 3 (symptomatic clinical disease) (Insel 2015, PMID 26404926).
  • The staging rests on prospective birth-cohort evidence: among children who seroconvert to multiple islet autoantibodies, 69.7% (95% CI 65.1–74.3) progress to clinical diabetes within 10 years, versus 14.5% with a single autoantibody and 0.4% by age 15 with none (Ziegler 2013, PMID 23780460).
  • Onset is not a childhood phenomenon: the estimated median age of onset globally is 39 years, and 64% of prevalent cases are aged 20–59 (Gregory 2022, PMID 36113507).
  • Presentation is frequently missed until crisis: a 233-study meta-analysis (380,191 participants, 58 countries) found 41.9% (95% CI 39.7–44.0) of children present in diabetic ketoacidosis at diagnosis, ranging from 15.6% (Sweden) to 78.5% (Thailand) (Zhang 2026, PMID 42303108).

Epidemiology and burden

Figure Value Source
People living with T1D worldwide, 2021 ~8.4 million (95% UI 8.1–8.8M) (Gregory 2022, PMID 36113507)
New diagnoses, 2021 ~0.5 million; ~35,000 died undiagnosed within 12 months of symptom onset (Gregory 2022, PMID 36113507)
Projected prevalence 2040 13.5–17.4 million (60–107% higher than 2021) (Gregory 2022, PMID 36113507)
Remaining life expectancy of a 10-year-old diagnosed in 2021 mean 13 years (low-income countries) to 65 years (high-income) (Gregory 2022, PMID 36113507)
Life-expectancy loss vs non-diabetic (Scotland 2008–2010, from age 20) 11.1 years (men), 12.9 years (women) (Livingstone 2015, PMID 25562264)
DKA at pediatric diagnosis, pooled worldwide 41.9% (Zhang 2026, PMID 42303108)
  • Onset before age 10 carries hazard ratios of 4.1 for all-cause mortality, ~30 for coronary heart disease and acute MI, and 12.9 for heart failure versus matched controls; risk falls sharply with later onset age (Rawshani 2018, PMID 30129464). Excess mortality persists across the T1D population even at target HbA1c (Rawshani 2017, PMID 28402770).
  • Diabetes overall (types combined) is among the fastest-growing GBD causes, with global prevalence projected to exceed 1.3 billion by 2050 (GBD 2021 Diabetes Collaborators 2023, PMID 37356446).
  • Even in the well-resourced US T1D Exchange registry (2016–2018), only 17% of youth and 21% of adults met ADA HbA1c goals; mean HbA1c peaked at 78 mmol/mol (9.3%) in ages 15–18 (Foster 2019, PMID 30657336).

Mechanism sketch

  • Genetically susceptible individuals (HLA DR3/DR4-DQ8 highest risk) develop islet autoimmunity, usually in early childhood; autoantibody seroconversion before age 3 and DR3/DR4-DQ8 accelerate progression (Ziegler 2013, PMID 23780460).
  • The disease progresses through predictable presymptomatic stages at variable rates, framing T1D as a continuum rather than an acute-onset event (Insel 2015, PMID 26404926); substages of presymptomatic disease can be resolved with progression-likelihood scoring (Weiss 2022, PMID 36028774).
  • Immunotherapy responses confirm the T-cell-driven model: anti-CD3 (teplizumab) expands exhausted-phenotype KLRG1+TIGIT+CD8+ T cells and delays onset (Herold 2019, PMID 31180194); β-cell-protective approaches (verapamil, targeting β-cell stress) partially preserve C-peptide independent of immunosuppression (Ovalle 2018, PMID 29988125; Forlenza 2023, PMID 36826844).
  • Notably, near-normalization of glucose alone with intensive automated delivery did not preserve β-cell function in newly diagnosed children — arguing that metabolic rest is not sufficient to halt autoimmune destruction (McVean 2023, PMID 36826834).

Treatment landscape

Glycemic management (anchor evidence and guidelines) - DCCT established that intensive insulin therapy reduces retinopathy development by 76%, microalbuminuria by 39%, and clinical neuropathy by 60%, at the cost of a 2–3-fold increase in severe hypoglycemia (DCCT 1993, PMID 8366922); 30-year follow-up (DCCT/EDIC) extended the benefit to cardiovascular outcomes (DCCT/EDIC 2016, PMID 26861924). - CGM-based targets are standardized by the international time-in-range consensus (>70% of time 70–180 mg/dL for most adults) (Battelino 2019, PMID 31177185). - Automated insulin delivery (AID) — the pivotal 6-month RCT of closed-loop control raised time in range from 61% to 71% versus no change (59%) with sensor-augmented pump therapy (Brown 2019, PMID 31618560). Meta-analyses across systems confirm TIR gains in adults and children (Di Molfetta 2024, PMID 39298688; Zeng 2023, PMID 38011519). ADA Standards of Care 2026 embed AID in routine T1D care (ADA 2026, PMID 41358889; pharmacologic approaches: PMID 41358900).

Disease modification - Teplizumab (anti-CD3) delayed clinical T1D in autoantibody-positive relatives: median time to diagnosis 48.4 vs 24.4 months, HR 0.41 (95% CI 0.22–0.78) (Herold 2019, PMID 31180194) — the basis of the first-ever FDA approval of a delaying therapy. In newly diagnosed (stage 3) children, two courses preserved stimulated C-peptide at 78 weeks (PROTECT; Ramos 2023, PMID 37861217). - Verapamil preserved ~30% higher C-peptide at 52 weeks in newly diagnosed pediatric T1D (Forlenza 2023, PMID 36826844), replicating the adult signal (Ovalle 2018, PMID 29988125). - β-cell replacement — zimislecel (VX-880), a stem-cell-derived fully differentiated islet product infused with immunosuppression, produced engraftment in all 14 participants and insulin independence in 10 of 12 at day 365 (Reichman 2025, PMID 40544428).

Screening and monitoring of early-stage disease - General-population screening is feasible: the Bavarian Fr1da program screened children for islet autoantibodies at scale (Raab 2016, PMID 27194320; yield reported in Ziegler 2020, PMID 31990315). - International consensus guidance now exists for monitoring autoantibody-positive (pre-stage 3) individuals (Phillip 2024, PMID 38912694).

Hypoglycemia and psychosocial burden - Impaired awareness of hypoglycemia remains a major driver of severe hypoglycemia in adults (Zammitt 2025, PMID 40386839), though its prevalence appears to be falling in the CGM era (Ali 2023, PMID 36645139). - Diabetes distress is common enough to be quantified by global meta-analysis (Peprah Osei 2026, PMID 42486409); fear of hypoglycemia degrades quality of life across ages (Zhang 2020, PMID 33091198), and AID use appears to reduce distress in users and caregivers (Canha 2025, PMID 39726162).

Research frontier

  • Extending anti-CD3 and combination immunotherapy from delay toward durable prevention, and defining who to treat at stage 1 vs stage 2 (Herold 2019, PMID 31180194; Phillip 2024, PMID 38912694).
  • Immunosuppression-free β-cell replacement (encapsulation, hypoimmune gene-edited islets) building on zimislecel's proof of concept (Reichman 2025, PMID 40544428).
  • Population screening economics and psychology: what infrastructure must follow a positive screen (Ziegler 2020, PMID 31990315).
  • Fully closed-loop (meal-announcement-free) systems and access equity for AID (Di Molfetta 2024, PMID 39298688; Foster 2019, PMID 30657336).

Heterogeneity that changes interpretation

T1D is one diagnosis but not one tempo. In TEDDY, 8,502 genetically high-risk children were followed for a median 9.9 years; those diagnosed before age 6 seroconverted at mean age 1.5 years and progressed after a mean 1.9 years, versus 3.5 and 5.4 years respectively among those diagnosed at ages 6–13 (Krischer 2021, PMID 34291312). Adult-onset disease more often has GADA predominance, fewer multiple autoantibodies, higher C-peptide at diagnosis, and less DKA than childhood-onset disease, which increases the risk of classification as type 2 diabetes (Leslie 2021, PMID 34670785).

Dimension Quantified observation Consequence
Autoantibody identity IA-2A positivity increased five-year progression risk 5.3-fold in single-antibody positivity, 2.2-fold within stage 1, and 1.3-fold within stage 2 Multiplicity alone leaves important risk variation
Age/tempo Mean autoantibody-to-diagnosis interval 1.9 years for TEDDY diagnosis before 6 vs 5.4 years at 6–13 Pediatric natural-history averages should not be applied unchanged to adults
Adult phenotype More GADA, fewer multiple antibodies, higher diagnostic C-peptide Negative or incomplete antibody panels do not safely exclude autoimmune diabetes
Geography Childhood registry incidence pooled at 20.16/100,000 (95% CI 16.49–23.84), with I²=89% A global mean conceals surveillance and true-risk heterogeneity
Care environment Pump use in a US pediatric registry was 61% in White, 26% in Black, and 39% in Hispanic participants Technology efficacy and technology delivery are separate questions

The IA-2A estimates came from 4,577 autoantibody-positive relatives in TrialNet; the wide childhood single-IA-2A confidence interval (HR 14.2, 95% CI 1.9–103.1) shows why subgroup models need external validation (Sims 2025, PMID 40016443). The registry meta-analysis pooled 51 studies and 433,727 participants from 38 countries, but incidence heterogeneity was extreme and diagnostic criteria differed (Chauhan 2026, PMID 42551241). The US treatment disparities persisted after socioeconomic adjustment, so household income alone did not explain outcome differences (Willi 2015, PMID 25687140).

Evidence tensions to retain

Question Evidence supporting one interpretation Counterweight
Is T1D primarily a β-cell-loss disease? C-peptide decline and insulin dependence track loss of secretory capacity Human pathology finds focal insulitis and surviving insulin-containing islets, not synchronous eradication
Does tighter glucose preserve β cells? Glucotoxicity and secretory stress provide a mechanism Intensive closed-loop glucose control did not preserve C-peptide in new-onset children (McVean 2023, PMID 36826834)
Are viral exposures causal? Enterovirus detection associated with islet autoimmunity (OR 2.1, 95% CI 1.3–3.3) and T1D (OR 8.0, 4.9–13.0) Observational designs and heterogeneous assays leave reverse causation and acceleration unresolved
Can genetic scores be population-wide gates? Scores aid classification and enrich surveillance A European-derived score discriminated T1D from type 2 diabetes less well in Indian than European data (AUC 0.84 vs 0.87)

The 2023 enterovirus synthesis included 60 studies and 12,077 participants; heterogeneity for the T1D association was I²=85%, so the pooled odds ratio is evidence of association rather than a universal attributable cause (Isaacs 2023, PMID 37390839). In India, HLA variants supplied most discriminative power and the score’s transport penalty was measurable, illustrating why ancestry calibration is a safety requirement (Harrison 2020, PMID 32528078).

Open questions

  • Can teplizumab's ~2-year delay be extended or repeated into indefinite prevention, and does earlier (stage 1) treatment work better? (Herold 2019, PMID 31180194; Ramos 2023, PMID 37861217)
  • Why does tight glycemic control from diagnosis fail to preserve β-cell function when verapamil partially succeeds — what is the β-cell-intrinsic pathway? (McVean 2023, PMID 36826834; Forlenza 2023, PMID 36826844)
  • Can stem-cell-derived islets work without lifelong immunosuppression, given deaths and neutropenia observed under current regimens? (Reichman 2025, PMID 40544428)
  • Which health-system models close the 52-year gap in remaining life expectancy for a child diagnosed in a low- vs high-income country? (Gregory 2022, PMID 36113507)
  • Is general-population autoantibody screening cost-effective where DKA-at-diagnosis rates are already low, and what follow-up burden does it create? (Ziegler 2020, PMID 31990315; Zhang 2026, PMID 42303108)
  • INDEX — master index for this condition; the Pages table there is the canonical page list.
  • Canonical sibling pages: staging-and-natural-history.md, epidemiology-and-burden.md, immunopathogenesis.md, genetics-and-environmental-triggers.md, insulin-therapy-and-technology.md, disease-modifying-immunotherapy.md, beta-cell-replacement.md, hypoglycemia.md, complications.md, screening-and-early-detection.md, guidelines.md, biomarkers.md, clinical-trials-landscape.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md.

References

The reference set below is a route into the domain-specific pages; it is not a substitute for their narrower evidence tables and controversy sections.

  1. Insel RA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38:1964-74. PMID 26404926
  2. Ziegler AG, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473-9. PMID 23780460
  3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86. PMID 8366922
  4. DCCT/EDIC Study Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016. PMID 26861924
  5. Herold KC, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381:603-613. PMID 31180194
  6. Ramos EL, et al. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med. 2023;389:2151-2161. PMID 37861217
  7. Brown SA, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381:1707-1717. PMID 31618560
  8. Di Molfetta S, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-analysis. Diabetes Metab Res Rev. 2024. PMID 39298688
  9. Zeng B, et al. Automated Insulin Delivery Systems in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-analysis of Outpatient Randomized Controlled Trials. Diabetes Care. 2023. PMID 38011519
  10. Gregory GA, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10:741-760. PMID 36113507
  11. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050. Lancet. 2023. PMID 37356446
  12. Zhang T, et al. Worldwide prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes: A systematic review and meta-analysis. Prev Med. 2026;210:108625. PMID 42303108
  13. Livingstone SJ, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015;313:37-44. PMID 25562264
  14. Rawshani A, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392:477-486. PMID 30129464
  15. Rawshani A, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017. PMID 28402770
  16. Foster NC, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21:66-72. PMID 30657336
  17. Battelino T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42:1593-1603. PMID 31177185
  18. Reichman TW, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. N Engl J Med. 2025;393:858-868. PMID 40544428
  19. Forlenza GP, et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023;329:990-999. PMID 36826844
  20. Ovalle F, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med. 2018. PMID 29988125
  21. McVean J, et al. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023. PMID 36826834
  22. Ziegler AG, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. 2020. PMID 31990315
  23. Raab J, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016. PMID 27194320
  24. Weiss A, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia. 2022. PMID 36028774
  25. Phillip M, et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care. 2024. PMID 38912694
  26. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358893
  27. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358889
  28. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358900
  29. American Diabetes Association Professional Practice Committee. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358896
  30. Zammitt NN, et al. Predictors of impaired awareness of hypoglycaemia and severe hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2025. PMID 40386839
  31. Ali N, et al. Fall in prevalence of impaired awareness of hypoglycaemia in individuals with type 1 diabetes. Diabet Med. 2023. PMID 36645139
  32. Peprah Osei E, et al. Global prevalence and correlates of diabetes distress in type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;239:113452. PMID 42486409
  33. Zhang Y, et al. Fear of hypoglycemia in patients with type 1 and 2 diabetes: a systematic review. J Clin Nurs. 2020. PMID 33091198
  34. Canha D, et al. The effect of automated insulin delivery system use on diabetes distress in people with type 1 diabetes and their caregivers: A systematic review and meta-analysis. Diabet Med. 2025. PMID 39726162
  35. Krischer JP, et al. Characteristics of children diagnosed with type 1 diabetes before vs after 6 years of age in the TEDDY cohort study. Diabetologia. 2021;64:2247-2257. PMID 34291312
  36. Leslie RD, et al. Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care. 2021;44:2449-2456. PMID 34670785
  37. Sims EK, et al. IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes. Diabetologia. 2025;68:993-1004. PMID 40016443
  38. Chauhan R, et al. Epidemiological and clinical insights from Type 1 Diabetes Global Registries. Diabetes Metab Syndr. 2026;20:103455. PMID 42551241
  39. Willi SM, et al. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics. 2015;135:424-434. PMID 25687140
  40. Isaacs SR, et al. Enteroviruses and risk of islet autoimmunity or type 1 diabetes. Lancet Diabetes Endocrinol. 2023;11:578-592. PMID 37390839
  41. Harrison JW, et al. Type 1 diabetes genetic risk score is discriminative of diabetes in non-Europeans. Sci Rep. 2020;10:9450. PMID 32528078